Podcast: Global HBV Disparities - HBV - Racial Disparities in HIV, HCV, and HBV - Infectious Disease

Tackling Racial Inequalities in HBV Care Globally

Listen as expert faculty, Geoffrey Dusheiko, FRCP, FRCP (Edin), FCP (SA), and Ming-Lung Yu, MD, PhD, discuss key racial inequities of care that lead to undertreatment for migrant populations and other racial minorities globally with or at risk for hepatitis B.

Geoffrey Dusheiko, FRCP, FRCP (Edin), FCP (SA)

Ming-Lung Yu, MD, PhD

Released: December 15, 2021

In this episode, Geoffrey Dusheiko, FRCP, FRCP (Edin), FCP (SA), and Ming-Lung Yu, MD, PhD, discuss key racial inequities of care that lead to undertreatment for migrant populations and other racial minorities globally with or at risk for hepatitis B. In addition, they discuss plans to improve engagement across the care continuum and strategies to combat implicit racial biases that affect optimal HBV care.

Topics include:

Differences in the burden of HBV globally
Suboptimal engagement of HBV care
Stigma associated with HBV care
Key strategies for overcoming racial barriers
First-hand patient stories

Information on this Educational Activity

Faculty

Geoffrey Dusheiko, FRCP, FRCP (Edin), FCP (SA)

Emeritus Professor of Medicine
Consultant Hepatologist
University College London Medical School
Professor
Liver Unit
Kings College Hospital
London, United Kingdom

Geoffrey Dusheiko, FRCP, FRCP (Edin), FCP (SA), has disclosed that he has received funds for research support from Abbott and consulting fees from Antios, Gilead Sciences, GlaxoSmithKline, Janssen, Lumira, Myr, and Roche.

Ming-Lung Yu, MD, PhD

Chair Professor
Hepatobiliary Division
Department of Internal Medicine and Hepatitis Center
Kaohsiung Medical University
Visiting Staff
Hepatobiliary Division
Department of Internal Medicine
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan

Ming-Lung Yu, MD, PhD, has disclosed that he has received funds for research support from Abbott, Bristol-Myers Squibb, Gilead Sciences, and Merck; consulting fee sform AbbVie, Abbott, Ascletis, Bristol-Myers Squibb, Gilead Sciences, Merck, and Roche; and fees for non-CME/CE services from AbbVie, Abbott, Bristol-Myers Squibb, Gilead Sciences, Ipsen, and Merck.